Therapeutics
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, Therapeutics sits in the top decile of US sponsors by registered trial count (#842 of 15,742 sponsors by registered trial count).
Therapeutics: 17 sponsored US clinical trials, none currently recruiting.
Therapeutics sponsors 17 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 17 completed. 7 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Plaque Psoriasis, with 4 trials.
Top-decile sponsor footprint
Therapeutics ranks in the top decile of sponsors by registered trial count (#842 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
17 of 17 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
17 total, page 1 of 1
Safety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea Pedis
NCT05363449
A Safety Study of 188-0551 Spray Versus Reference Listed Drug (RLD) in Adult Subjects With Plaque Psoriasis
NCT04080206
A Study of the Safety and Efficacy of UHE-105 Shampoo in Subjects With Scalp Psoriasis
NCT04243486
A Comparison Study of UHE-103 Cream in Subjects With Moccasin Type Tinea Pedis
NCT03897257
A Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis
NCT03759197
Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis (307)
NCT03731052
A Phase 2 Safety and Efficacy Study of UHE-101 Cream in Subjects With Acne Vulgaris
NCT03307577
A Comparison of 188-0551 Solution Versus Vehicle Solution in Subjects With Plaque Psoriasis (Study 203)
NCT03065556
A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 310)
NCT02742441
A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis
NCT02367911
A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 306)
NCT02368210
A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -305)
NCT01882647
A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -304)
NCT01871402
A Study to Determine the Efficacy and Safety of 122-0551 in Subjects With Plaque Psoriasis
NCT01700985
Pharmacokinetics of 122-0551 and Its Effects on Adrenal Suppression
NCT01698333
A Study to Determine the Efficacy and Safety of Halobetasol Propionate Lotion 0.05% in Subjects With Plaque Psoriasis
NCT01610596
Blinded Study of Topical Investigational Lotion Vs. Approved Cream in Treatment of Plaque Psoriasis
NCT01166646
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 9 |
| Phase 3 | 7 |
Therapeutic Areas
How the Therapeutics archive is shaped
17 indexed studies, none listed as recruiting (0% open); 17 completed (100%).
Phase mix: 7 late (III/IV) vs 10 early (I/II) (balanced across stages).
Top condition: Plaque Psoriasis (4 trials), 2 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Therapeutics: archived-pipeline peers nationwide
Peers matched on 17 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 17 archived trials
- Achieve Life Sciences · 17 trials · 0% recruiting
- BioDelivery Sciences International · 17 trials · 6% recruiting
- Chugai Pharmaceutical · 17 trials · 24% recruiting
- ConvaTec · 17 trials · 18% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Therapeutics page
17 registered trials is a research-attention snapshot, not an endorsement of Therapeutics or any single study.
- None of Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Plaque Psoriasis is the condition Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Plaque Psoriasis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Therapeutics pipeline card: 17 registered trials from official public datasets.Report a data error.